MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway

Gefitinib is a first line anti-tumor drug used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, the drug resistance to gefitinib limits its clinical application. Here, we observed the CSCs of PC9 are obviously resistant to gefitinib compared wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jingjin, Feng, Xiaoning, Zhou, Wenjing, Wu, Yue, Yang, Yunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341972/
https://www.ncbi.nlm.nih.gov/pubmed/27690301
http://dx.doi.org/10.18632/oncotarget.12283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341972/
https://www.ncbi.nlm.nih.gov/pubmed/27690301
http://dx.doi.org/10.18632/oncotarget.12283

Ejemplares similares